Metformin Glycinate in Patients With MS or DM2 , Hospitalized With COVID-19 and SARS Secondary to SARS-CoV-2
Status:
Withdrawn
Trial end date:
2021-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of metformin glycinate at
dose of 620 mg twice per day plus standard treatment comparing to standard treatment alone
(we will use placebo) of patients who have metabolic syndrome or type 2 diabetes, which have
severe acute respiratory syndrome secondary to SARS-CoV-2.